On 27 October 2025, a General Assembly meeting of stakeholders of the Latvian Medicines Verification Organisation (LZVO) was held. During the meeting, participants discussed the planned activities and projects for the coming year, as well as approved the budget for 2026.
The General Assembly also approved the fixed annual fee for 2026 for the marketing authorisation holders (MAHs), including parallel importers and parallel distributors of medicines in the territory of Latvia, in accordance with the financing policy for the maintenance and development of the Latvian Medicines Verification System.
It was decided to maintain the fixed annual fee for each MAH at EUR 2,500 for 2026.
During November, in the closed section of the customer portal, LZVO will inform all MAH contacts about the fixed annual fee for the upcoming year.
MAH representatives are invited to contact LZVO at info@lzvo.lv for any questions concerning the annual fee or other current events.